News & Publications
Healthcare Markets International meets Dr Felix Dahm
Dayton Therapeutics, a Switzerland-based clinical oncology company led by a team of experienced oncologists, was established with the aim of identifying compounds for the treatment of new cancer indications with limited therapeutic…
Read more
Anticancer Research: Satraplatin Demonstrates High Cytotoxic Activity…
Satraplatin is an oral platinum analog with proven clinical efficacy and a more favorable toxicity profile, although with increased hematotoxicity, when compared to cisplatin…
Read more
Nature Reviews: The rediscovery of platinum-based cancer therapy
Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was approved in 1978. More than 40 years later, even in the era of precision medicine and immunotherapy…
Read more
Nature Reviews: Platinum-(IV)-derivative satraplatin…
Platinum-(IV)-derivative satraplatin represents a new generation of orally available anti-cancer drugs that are under development for the treatment of several cancers. Understanding the mechanisms of cell cycle modulation and apoptosis is…
Read more
American Society of Hematology: Promising activity of nelfinavir-…
Treatment of proteasome inhibitor (PI)-refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, alone…
Read more
Yahoo! Finance: Dayton Therapeutics Discovers New…
Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…
Read more
Markets Insider: Dayton Therapeutics Discovers New…
Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…
Read more
Bloomberg UK: Dayton Therapeutics Discovers New…
Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…
Read more
Market Watch: Dayton Therapeutics Discovers New…
Dayton Therapeutics has announced that the company is using its AI-powered genetic and molecular research model for investigating new therapeutic uses of clinical stage drug candidates where development has been discontinued – in particular satraplatin. Satraplatin is…
Read more